Business Context and Reporting Period
This Form 8-K was filed by Palisade Bio, Inc. (formerly Seneca Biopharma, Inc.) on June 16, 2021, reporting events occurring on June 11, 2021. The filing details the finalization of share disbursements and warrant adjustments related to a private placement transaction completed in connection with the company's merger with Leading Biosciences, Inc. on April 27, 2021.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the capital structure adjustments from the Pre-Merger Financing:
- Initial Financing Amount: $20.0 million raised from Altium Growth Fund, LP.
- Initial Additional Shares: 3,977,676 shares placed in escrow.
- Initial Warrant: Issued May 20, 2021, for 4,995,893 shares at $4.70 per share.
Material Changes
On June 11, 2021, a reset event occurred under the Securities Purchase Agreement, resulting in the following material changes:
- Escrow Release: The final 307,675 Additional Shares remaining in escrow were disbursed to the Investor.
- Warrant Adjustment: The Equity Warrant was automatically adjusted to increase the number of shares exercisable to 5,303,568 and lower the exercise price to $3.88 per share.
Outlook, Risks, and Contingencies
The filing outlines the mechanics of the price protection provisions in the Securities Purchase Agreement, which trigger share issuances or warrant adjustments if the company's stock price falls below specific thresholds during defined periods (45th, 90th, and 135th days post-merger). The June 11 event represents the final adjustment under these specific terms for the initial financing tranche. No forward-looking guidance or new risk factors were disclosed in this specific report.
Investor Verification Checklist
- Verify the total number of shares issued to Altium Growth Fund, LP following the June 11 reset (307,675 shares).
- Confirm the updated terms of the Equity Warrant (5,303,568 shares at $3.88 exercise price).
- Review the company's current cash position to assess runway following the $20.0 million financing.
- Monitor future stock price performance to determine if further adjustments are triggered under any remaining provisions of the agreement.